Novitium/Ani Ph Patent-Cliff Exposure & CMS Drug Spending Portfolio

Novitium/Ani Ph (US): 3 reconciled FDA prescription therapies, $1.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$1.3M
2024 Medicare Part D Spend$388K
2024 Medicaid Spend$906K
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel